Conditionally replicative adenoviruses (CRAd) are under investigation as anticancer agents. Previously, we found that the CRAd Ad#24-p53, expressing the p53 tumor suppressor protein from its genome, more effectively killed most human cancer cells than did its parent Ad#24. However, a minority of cancer cell lines poorly responded to the oncolysis-enhancing effect of p53. Here we show that refractory cell lines expressed high levels of the major negative p53 regulator murine double minute 2 (MDM2).
Introduction
Conditionally replicative adenoviruses (CRAd) represent a rapidly expanding novel class of anticancer agents. They are designed to selectively replicate in tumor cells and to destroy these cells by inducing lysis (1 -3) . The oncolytic effect of CRAds is amplified by in situ virus multiplication and spread to adjacent cells following lysis of infected tumor cells. The first clinical trials with CRAds have shown the safety of CRAds but have also shown that their oncolytic potency needs to be improved. Preclinical studies have shown several ways to accomplish this, including tropism modification, therapeutic transgene expression, and combination with other therapies (3) .
Previously, we and others found that adenoviruses can be made into more effective oncolytic agents by expressing exogenous p53 tumor suppressor protein in infected cancer cells (4 -6) . The human p53-expressing CRAd AdD24-p53 more effectively killed most human cancer cell lines tested in vitro than did its parent AdD24 (4) . Recently, we expanded this finding on primary human glioma and neuroblastoma cells in vitro and on xenografts in vivo (7, 8) . Only few cancer cell lines were refractory to the oncolysis-enhancing effect of exogenous p53. Among these were cell lines with p53 wild-type, mutant, and null genotypes (4) .
In search for a molecular determinant of resistance against the oncolysis-enhancing effect of exogenous p53, we focused our attention on the major negative p53 regulator oncoprotein murine double minute 2 (MDM2). MDM2 overexpression, due to gene amplification, is most frequently found in soft tissue sarcomas, osteosarcomas, and esophageal carcinomas (9) . MDM2 directly binds to p53 and inhibits its transcriptional activity (10 -12) . In addition, MDM2 binding induces p53 nuclear export (13) and targets p53 for proteolytic degradation (14, 15) . Hence, high MDM2 expression might inhibit p53-mediated oncolysis enhancement by efficient inactivation of exogenous p53.
Here we show that several cell lines that poorly responded to oncolysis enhancement by p53 constitutively expressed high levels of MDM2. To obviate MDM2-mediated inactivation of CRAd-encoded p53, we constructed the new CRAd AdD24-p53(14/19) that expresses a p53 variant incapable of binding to MDM2 (16) . This new CRAd was more effective in killing cancer cells with high levels of human MDM2. This finding suggests that knowledge on molecular defects in cancer cells can be used to design tailored CRAds with augmented oncolytic potency. Recombinant Adenoviruses CRAds AdD24 and AdD24-p53 were previously described (4). To construct AdD24-p53(14/19), two single nucleotide substitutions (T>A and T>G) that change amino acids 14 and 19 from L to Q and from F to C, respectively, were introduced into the p53 gene on plasmid pABS.4-p53 (4) by PCR-mediated site-directed mutagenesis using Pfu polymerase (Stratagene, La Jolla, CA). First, two PCR amplification products were made from pABS.4-p53 using upstream primer 5V-CGTTTC-CCGTTGAATATGGC-3V and mutation primer 5V-CTGAACATGTTTCCTGACTCTGAGGGGGCTC-3V, and downstream primer 5V-GAAGTCTCATGGAAGCCAGC-3V and mutation primer 5V -CCTCAGAGTCAGGAAA-CATGTTCAGACC-3V, respectively. Next, the two amplification products were mixed and amplified using the upstream and downstream primers to generate a fulllength amplification product containing the nucleotide substitutions. The wild-type Simian virus 40 early promoter (SVE)-p53 expression cassette from pABS.4-p53 was subcloned into the KpnI and SalI sites in the multiple cloning site of a pBluescriptSKÀ derivative with deleted SmaI restriction site to create pBSKDSma-p53. The 568 bp KpnI/SmaI fragment from the PCR product encompassing the two mutations was used to replace the corresponding wild-type p53 fragment in pBSKDSma-p53, creating pBSKDSma-p53 (14/19 Western Blot Analysis Cells (where indicated, 24 hours after infection with AdD24-p53 or AdD24-p53(14/19) at 100 pfu/cell) were harvested from plate cultures and lysed in 200 AL of 140 mmol/L NaCl, 0.2 mol/L triethanolamine, 2 g/L deoxychelate, 1 mmol/L phenylmethanesulfonylfluoride, and 50 Ag/AL antipain by three freeze/thaw cycles. Lysates were cleared by centrifugation and protein concentrations were determined using the BCA Protein Assay Kit (Pierce, Rockford, IL). Equal amounts (15 Ag for p53 and h-actin blots or 50 Ag for MDM2 blots) of protein were separated on 7.5% or 10% SDS-PAGE gel and transferred to polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA). Immunoblots were processed according to standard procedures, using mouse monoclonal antibody SMP14 (DAKO, Glostrup, Denmark) for MDM2, PAb 1801 (NeoMarkers, Fremont, CA) directed against p53 amino acids 32 to 79, or AC-15 (Sigma, St. Louis, MO) for h-actin, followed by anti-immunoglobulin G-horseradish peroxidase conjugate (DAKO) and ECL or ECL PLUS chemiluminescence detection reagent (Amersham Biosciences, Roosendaal, the Netherlands).
Materials and Methods

Cell Lines
Analysis of (Mutant) p53 Stability MG-63 cells were grown in six-well cultures until f70% confluence. The cells were subjected to 250 pfu/cell AdD24-p53 or AdD24-p53(14/19) for 1 hour and incubated in fresh medium at 37jC and 5% CO 2 . Twenty-four hours postinfection, the medium was replaced with medium containing 30 or 60 Ag/mL cycloheximide (Sigma) in two experiments and cells were cultured for 0, 1, or 4 hours before harvesting for Western blot analysis as above, using 35 Ag protein and primary monoclonal antibodies 1801 and AC-15. Band intensities on X-ray film were measured on a BioRad GS-700 imaging densitometer and analyzed using Quantity One software (Bio-Rad Laboratories, Veenendaal, the Netherlands). Approximate p53 half-lives were calculated from the average h-actin normalized signals from two independent experiments.
p53 Reporter Assay The reporter cell line SaOs-2/PG-13 was made by cotransfecting SaOs-2 cells with the p53-dependent reporter plasmid PG13-Luc (17), carrying the firefly luciferase gene driven by a p53-dependent promoter and pTK-hyg (Clontech, Palo Alto, CA); carrying the hygromicin resistance gene driven by a minimal herpes simplex virus thymidine kinase promoter in a 10:1 molecular ratio using Lipofectamine PLUS (Life Technologies) according to the method described by the manufacturer; and selecting stable transfectants with 200 Ag/mL hygromicin B (Roche Diagnostics) for 2 weeks. To assess p53-specific transactivation as a result of adenovirus infection and exogenous p53 introduction, SaOs-2/PG-13 cells were seeded at 5 Â 10 4 per well in 24-well plates and infected the next day with AdD24-p53 or AdD24-p53(14/19) for 1 hour at 100 pfu/cell. After 24 hours of culture at 37jC, the luciferase expression in the cells was measured using the Luciferase Chemiluminescent Assay System (Promega, Madison, WI) and a Lumat LB 9507 luminometer (EG&G Berthold, Bad Wildbad, Germany). Transactivation is expressed as relative luciferase activity compared with mock-treated SaOs-2/PG-13 cells.
Assay for Oncolytic Activity of CRAds on Cancer Cells Cells were seeded 5 Â 10 4 cells per well in 24-well plates and cultured overnight. The next day, they were infected with AdD24, AdD24-p53, or AdD24-p53(14/19) at a dose range of 1 to 10 À3 pfu/cell for 1 hour at 37jC. The cells were subsequently cultured for up to 3 weeks at 37jC with 50% medium changes twice weekly for most cell lines, or every other day for MKN45 cells. Cultures were maintained until cytopathic effects were evident in AdD24-infected cultures (i.e., for 12 -20 days for different cell lines). The culture medium was then removed and adherent cells were stained with crystal violet dye as described (4).
Results and Discussion
Cell Lines Resistant to p53-Mediated Oncolysis Enhancement Express High Levels of MDM2
Previously, we tested a large panel of human cancer cell lines for susceptibility to treatment with AdD24 or AdD24-p53 (4, 7, 8) . Among these, we identified only five cell lines (i.e., A2780, MKN45, SF763, MNNG-HOS, and MG-63) that were not more rapidly killed by AdD24-p53 than by AdD24. The p53 genotypes of these cell lines did not hint at an explanation for their unresponsiveness to exogenous p53 expression. We envisioned that effective degradation of exogenous p53 in these cancer cell lines could perhaps have limited the efficacy of AdD24-p53 treatment. This prompted us to analyze expression of the major negative p53 regulator MDM2 by Western blot analysis. In addition, with two of the refractory cell lines being osteosarcoma cell lines, of three osteosarcoma cell lines tested, this cancer type seemed overrepresented. Because MDM2 is often amplified in osteosarcoma (9, 11), we also analyzed the osteosarcoma cell line SaOs-2, which is moderately sensitive to p53-mediated oncolysis enhancement (4), and osteosarcoma cell lines U2OS and CAL-72, which we had not included in our studies before. Figure 1 shows that the cell lines expressed various MDM2 isoforms, consistent with the existence of different MDM2 splice variants in cancer cells (18) . All five refractory cell lines and CAL-72 cells expressed higher levels of 90 kDa full-length human MDM2 than did U2OS and SaOs-2. In addition, all cell lines except U2OS expressed an MDM2 species with slightly reduced molecular weight, possibly representing the f85 kDa isoform expressed from the full-length transcript (19, 20) . MKN45, A2780, and SF763 cells displayed particularly high MDM2 levels with, in addition to the high molecular weight species, several smaller molecules. Together, these findings showed that resistant cell lines constitutively overexpressed MDM2, suggesting that this might be a determinant of resistance against the oncolysisenhancing effect of exogenous p53.
Construction and Characterization of Ad#24-p53 (14/19) To obviate a possible inhibitory effect of MDM2, we decided to construct a new AdD24-derived CRAd expressing a p53 variant resistant to MDM2-mediated degradation. Several such p53 variants have been described, including p53(14/19) and p53(22/23) with amino acid substitutions in the MDM2 binding domain (16) , p53(d 13 -19) with a deletion in the MDM2 binding site (15) , and the chimeric p53 analogue CTS1 in which the entire NH 2 -terminal domain comprising the MDM2 binding site was replaced by the herpes simplex virus VP16 transactivation domain (21) . The variants p53(14/19), p53(d 13 -19) , and CTS1 have already been introduced into cancer cells with high MDM2 expression by means of replication-deficient adenovirus vectors and shown to confer growth inhibition and apoptosis induction in these cells (22 -25) . In this respect, p53(22/23) that lacks transactivation function was less effective (25, 26) . The MDM2 binding domain in p53 partially overlaps with the binding site for adenovirus (16) . Because the mechanism of oncolysis enhancement by p53 has not yet been resolved, we decided to use a p53 variant that leaves its transactivation and complex formation functions intact as much as possible. The p53(14/19) variant was reported to retain f50% transactivation activity and 60% E1B-55K binding (16) . We chose this variant and constructed the new CRAd AdD24-p53(14/19), which is identical to AdD24-p53 except for amino acid substitutions L14Q and F19S. AdD24-p53(14/19) was characterized in comparison with its parent AdD24-p53 by infecting p53-null, MDM2-low SaOs-2 cells and measuring p53 expression and transactivation activity 24 hours later (Fig. 2) . Western blot analysis using monoclonal antibody 1801, which is directed against a p53 epitope distinct from the mutations in p53 (14/19) , showed comparable p53 signals in AdD24-p53 -and AdD24-p53(14/19) -infected cells ( Fig. 2A) . Assuming that the mutation did not affect antibody binding affinity, this suggested that the two variants accumulated to similar levels. Transactivation function was analyzed by measuring the activity of luciferase driven by a p53-dependent promoter (Fig. 2B ). For this, we used SaOs-2/PG13-Luc, a cell line derived from SaOs-2 by stable transfection with the p53 reporter construct PG13-Luc (17) . As can be seen, infection with AdD24-p53 caused p53 promoter transactivation, increasing luciferase expression by f7-fold. AdD24-p53(14/19) infection elevated luciferase activity f3-fold, indicating that the amino acid substitutions in p53(14/19) partially affected its specific transactivation function. This was consistent with the moderate loss of transactivation activity previously reported for this variant (16) .
CRAd-Encoded p53(14/19) Exhibits a Prolonged Halflife in MDM2-Overexpressing Cancer Cells
In adenovirus-infected, MDM2-overexpressing cells, wild-type p53 is degraded via E1B-55K -and E4orf6-mediated ubiquitination (27) as well as through MDM2-mediated ubiquitination, whereas p53(14/19) is resistant to MDM2-mediated degradation (16, 25, 26) , but is still subject to adenovirus protein -mediated ubiquitination. We investigated relative stabilities of CRAd-encoded p53 and p53 (14/19) in the face of MDM2 overexpression. MDM2-high, p53-null MG-63 cells were infected with the CRAds at a high multiplicity of infection and, 24 hours later, cycloheximide was added to inhibit de novo protein translation. Immediately thereafter, and 1 and 4 hours later, cell lysates were prepared and p53 was detected by Western blot analysis (Fig. 3) . As can be seen, the amounts of CRAd-encoded wild-type p53 and p53(14/19) both declined. In two independent experiments, p53 was lost faster than p53(14/19). Approximate half-lives estimated from these experiments were 38 and 80 minutes for p53 and p53(14/19), respectively. The longer presence of p53(14/19) might suggest that adenovirus protein -mediated p53 degradation is less efficient than MDM2-mediated degradation. Alternatively, the moderate decrease in binding affinity of p53(14/19) to E1B-55K (16) may have affected adenovirus protein -mediated degradation.
Oncolytic Potency of Ad#24-p53(14/19) against Human MDM2-Overexpressing Cells Finally, we determined the oncolytic potencies of AdD24, AdD24-p53, and AdD24-p53(14/19) against A2780, MKN45, SF763, MG-63, and MNNG-HOS cells, known to be similarly susceptible to AdD24 and AdD24-p53 (i.e., cells not responsive to p53-mediated oncolysis enhancement), and against SaOs-2 cells that are more effectively killed by AdD24-p53 than by AdD24 (4). In addition, we included MDM2-low U2OS and MDM2-high CAL-72 cells that we had not previously evaluated for susceptibility to CRAd treatment. Cells were inoculated with each virus in a range of 1 to 0.001 pfu/cell and cultured for up to 3 weeks until cytopathic effects became evident in AdD24-infected cultures. Remaining attached cells were then stained with crystal violet to assess relative CRAd cytotoxicity. At the low multiplicities of infection used, AdD24 did not exert detectable toxicity on A2780 and MG-63 cells within 3 weeks. These cells required 100 pfu/cell or more to be eradicated (not shown). As can be seen in Fig. 4 , AdD24-p53 was clearly more effective than AdD24 in killing MDM2-low U2OS cells, eradicating cell monolayers after infection with a 100-fold lower CRAd inoculum. MDM2-low SaOs-2 cells were also more effectively killed by AdD24-p53 than by AdD24, but not in all experiments. On average, oncolysis enhancement in SaOs-2 cells was less than 10-fold. In contrast, wild-type p53 expression did not at all enhance oncolysis of any of the MDM2-high cell lines, consistent with earlier observations. Hence, only MDM2-low cells were more susceptible to the wild-type p53-expressing CRAd, substantiating the notion that MDM2 overexpression correlates with resistance to p53-dependent oncolysis enhancement. Most importantly, the new CRAd AdD24-p53(14/19) expressing MDM2-binding deficient p53 was f10 times more effective than either AdD24 or AdD24-p53 in killing MDM2-high cells. AdD24-p53(14/19) was, however, less effective than AdD24-p53 against MDM2-low cells. This was confirmed on a larger panel of cancer cell lines previously shown to be highly susceptible to p53-mediated oncolysis enhancement (not shown). These findings showed that the efficacy enhancement through abrogation of MDM2 binding was specific and could not be explained by minor differences in viral titers. On MDM2-low cells, where p53 inhibition through MDM2 binding should be insignificant, mutation of the MDM2 binding site in p53 reduced CRAd efficacy, possibly due to reduced p53 transcriptional activity (see above). The mutations introduced into p53 to enhance CRAd efficacy against MDM2-high cancer cells were thus at the expense of a general decline in its oncolysis-enhancing activity. Therefore, the contribution of MDM2-binding inhibition to p53-mediated oncolysis enhancement in MDM2-overexpressing cancers was probably even underestimated. In the aggregate, AdD24-p53(14/19) seems a more effective agent for virotherapy treatment of the subset of MDM2-high cancers, rather than a generally more efficacious anticancer agent. For most cancers, previously constructed AdD24-p53 remains the preferred agent.
In conclusion, our results support the general notion that expression of functional p53 tumor suppressor protein augments the anticancer efficacy of CRAds. We designed tailored CRAd AdD24-p53(14/19) for a more effective oncolysis of cancer cells with constitutive MDM2 overexpression. Similar strategies might perhaps be followed to increase CRAd efficacy against cancers expressing other p53 inhibitors, such as human papillomavirus E6 protein, hepatitis B virus X protein, p53-associated Parkin-like cytoplasmic protein, or COP1 (28 -31) . This way, a library of CRAds targeted for different genetic aberrations in cancer could be compiled. Linking this repertoire of targeted therapeutics to the promise of functional genomics and proteomics technologies might contribute to the advance of individualized molecular medicine, wherein each patient is treated with a tailored CRAd designed to meet the genetic changes in that patient's particular tumor, resulting in a more effective virotherapy. Semiquantitative assessment of oncolytic potency shows that AdD24-p53 is f100-fold more potent than AdD24 against U2OS, 10-fold more potent against SaOs-2 cells, and similarly potent against the other four cell lines. AdD24-p53(14/19) is f10 times less potent than AdD24-p53 against the two MDM2-low cell lines, but at least 10 times more potent against the four MDM2-high cell lines. Representative of at least three independent experiments on each cell line. 
